Clene 2025 net loss narrows as expenses fall

Clene

12/03/2026 12:08

Overview

US biopharma firm's 2025 net loss narrowed as operating expenses declined year over year

Lower R&D and admin costs followed completion of key clinical trial phases

Company raised $28 mln in oversubscribed financing, extending cash runway into 2027

Outlook

Clene plans to file NDA for CNM-Au8 in ALS by end of June 2026

Company expects cash runway to end of Q3 2026, with financing extending into 2027

Clene expects FDA Type C meeting minutes early in Q2 2026

Result Drivers

LOWER R&D SPENDING - Decreased research and development expenses due to completion of blinded phases and open-label extensions of key ALS trials, and higher grant revenue related to NIH-EAP enrollment

LOWER ADMINISTRATIVE COSTS - General and administrative expenses fell due to lower insurance, legal, investor relations, and personnel costs

LOWER INTEREST AND ONE-TIME EXPENSES - Other expense declined due to lower interest expense and absence of one-time losses from prior year

Company press release: ID:nGNX8jB7Tc

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$26.17 mln
FY Basic EPS
-$2.65
FY Income From Operations
-$23.08 mln
FY Operating Expenses
$23.28 mln
FY Pretax Profit
-$26.17 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Clene Inc is $30.00, about 437.6% above its March 11 closing price of $5.58

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)